Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 1/20 | 0.40 |
| ▸ | CA2 | P00918 | 1/20 | 0.40 |
| ▸ | CA9 | Q16790 | 1/20 | 0.40 |
| ▸ | APLNR | P35414 | 3/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | PKM | P14618 | 1/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20604256 | 1.00 | CA1 (0.40) | CA1CA2CA9APLNRKDM4E | |
| SCHEMBL20604241 | 0.73 | APLNR (0.41) | APLNRKDM4EPKMMEN1KMT2A | |
| SCHEMBL20604242 | 0.73 | APLNR (0.41) | APLNRKDM4EPKMMEN1KMT2A | |
| SCHEMBL15199517 | 0.73 | KDM4E (0.39) | APLNRKDM4EPKMMEN1KMT2A | |
| SCHEMBL31744437 | 0.72 | KDM4E (0.34) | KDM4EPKMKMT2A | |
| SCHEMBL6870706 | 0.71 | KDM4E (0.39) | KDM4EPKMMEN1KMT2A | |
| SCHEMBL20604308 | 0.69 | CA1 (0.41) | CA1CA2CA9MEN1KMT2A | |
| SCHEMBL20604310 | 0.69 | CA1 (0.41) | CA1CA2CA9MEN1KMT2A | |
| SCHEMBL20604361 | 0.69 | CA1 (0.41) | CA1CA2CA9MEN1KMT2A | |
| SCHEMBL8683323 | 0.67 | KDM4E (0.43) | KDM4EPKMMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3423433-B1 | SULFAMATE DERIVATIVE COMPOUNDS, PROCESSES FOR PREPARING THEM AND THEIR USES | BIO PHARM SOLUTIONS CO LTD (KR) | 2025-12-17 | — | — | EP | claimed |
| US-10351519-B2 | Sulfamate derivative compounds, processes for preparing them and their uses | BIO-PHARM SOLUTIONS CO., LTD. (KR) | 2019-07-16 | — | — | US | claimed |
| EP-3423433-A1 | SULFAMATE DERIVATIVE COMPOUNDS, PROCESSES FOR PREPARING THEM AND THEIR USES | Bio-Pharm Solutions Co., Ltd. (KR) | 2019-01-09 | — | — | EP | claimed |
| EP-3423433-B1 | SULFAMATE DERIVATIVE COMPOUNDS, PROCESSES FOR PREPARING THEM AND THEIR USES | BIO PHARM SOLUTIONS CO LTD (KR) | 2025-12-17 | — | — | EP | disclosed |
| US-10351519-B2 | Sulfamate derivative compounds, processes for preparing them and their uses | BIO-PHARM SOLUTIONS CO., LTD. (KR) | 2019-07-16 | — | — | US | disclosed |
| EP-3423433-A1 | SULFAMATE DERIVATIVE COMPOUNDS, PROCESSES FOR PREPARING THEM AND THEIR USES | Bio-Pharm Solutions Co., Ltd. (KR) | 2019-01-09 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10351519-B2 | Sulfamate derivative compounds, processes for preparing them and their uses | STS, SULT2A1, SULT1A1 | CA1 300/4885CA2 576/4885CA9 674/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.